β-lactam/β-lactamase inhibitor combinations

The development of β-lactam/β-lactamase inhibitors seems to be expanding rapidly and promise to be the best short-term strategy against the most recalcitrant Gram-negative pathogens. In this podcast, we will discuss the current state of the art in this field
Objectives:
• Discuss how the discovery of β-lactam/β-lactam inhibitors has evolved
• Review the current state-of-the-art of developing of novel β-lactam/β-lactamase inhibitors
• Analyze the current and future clinical applications of these drugs against major antimicrobial-resistant pathogens.
Visit aac.asm.org to read more and subscribe to the podcast at asm.org/eic

[@patienceebazuaye-alonge3746]

Thank you.

[@sindibin]

Thanks, so useful

[@ccbowers]

20:30 I suspect she just misspoke, but PDCs are class C beta-lactamases ( ampC) , not class B.

[@boitech9584]

1st view